RAP1A

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, RAP1A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAP1A data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RAP1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAP1A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, THCA, and CHOL are the cancer types where RAP1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
SKCMDFSMedianII,III,IV0.0290.683<.00112view →
THCADFSMedianAll0.1610.829.0079view →
CHOLOSMedianAll0.1550.725.0293view →
UCECOSMedianAll1.0000.662.0452view →
Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAP1A–SKCM (DFS)

Kaplan–Meier survival curve for RAP1A mutant vs wild-type samples in SKCM.

Open the SKCM breakdown →

Exploration